Table 7. The proportional hazard assumption in univariate and multivariate Cox regression analysis of predictors of progression-free survival and overall survival in 64 metastatic colorectal cancer patients.
| Progression-free survival | Overall survival | |||||||
|---|---|---|---|---|---|---|---|---|
| Variables | Univariate analysis HR (95% CI) |
p-value | Multivariate analysis HR (95% CI) |
p-value | Univariate analysis HR (95% CI) |
p-value | Multivariate analysis HR (95% CI) |
p-value |
| Age, years (<65 vs. ≧65) |
0.779 (0.386–1.575) | 0.487 | 0.979 (0.433–2.217) | 0.960 | 1.674 (0.720–3.890) | 0.231 | 2.377 (0.943–5.991) | 0.066 |
| Gender (female vs. male) | 1.380 (0.685–2.779) | 0.372 | 2.207 (0.871–4.715) | 0.101 | 1.065 (0.454–2.498) | 0.885 | 1.838 (0.614–5.495) | 0.276 |
| Chemotherapy/targeted therapy cycles (=6 vs. ≥7) | 0.237 (0.116–0.483) | <0.001* | 0.180 (0.073–0.440) | <0.001 * | 0.094(0.033–0.269) | <0.001* | 0.036 (0.008–0.159) | <0.001* |
| Metastectomy location Liver Lung Ovary |
0.577 (0.276–1.207) 0.834 (0.545–1.907) 1.00 |
0.144 0.285 |
0.595 (0.185–1.301) 0.912 (0.512–1.952) 1.00 |
0.288 0.355 |
1.154 (0.475–2.805) 1.015 (0.501–2.521) 1.00 |
0.752 0.683 |
1.254 (0.452–3.012) 1.352 (0.522–2.652) |
0.652 0.412 |
| Synchronous/Metachronous Synchronous Metachronous |
1.125 (0.798–1.586) 1.00 |
0.500 |
0.999 (0.418–2.389) 1.00 |
0.998 |
1.064 (0.693–1.633) 1.00 |
0.778 |
0.499 (0.175–1.428) 1.00 |
0.195 |
|
RAS Status Wild Mutant |
2.879 (1.297–6.390) 1.00 |
0.009 * |
9.787 (2.518–38.033) 1.00 |
0.001 * |
0.431 (0.099–1.880) 1.00 |
0.263 |
0.332 (0.065–1.694) 1.00 |
0.185 |
| Pre-treatment CEA (ng/ml) ≧5 <5 |
1.195 (0.556–2.565) 1.00 |
0.644 |
1.051 (0.378–2.918) 1.00 |
0.924 |
2.122 (0.620–7.265) 1.00 |
0.231 |
1.529 (0.339–6.9.4) 1.00 |
0.581 |
| Post-treatment CEA (ng/ml) ≧5 <5 |
1.005 (1.001–1.008) 1.00 |
0.025* |
1.842 (0.795–4.265) 1.00 |
0.154 |
1.729 (0.741–4.027) 1.00 |
0.204 |
1.452 (0.469–4.495) 1.00 |
0.517 |
| Type of targeted therapy Cetuximab Bevacizumab |
0.958(0.683–1.346) 1.00 |
0.806 |
2.083 (0.734–5.932) 1.00 |
0.168 |
0.944 (0.612–1.456) 1.00 |
0.795 |
0.314 (0.103–0.955) 1.00 |
0.041 * |
| Grade III or more adverse effect Yes No |
0.976 (0.627–1521) 1.00 |
0.916 |
0.387 (0.130–1.158) 1.00 |
0.090 |
1.084 (0.586–2.003) 1.00 |
0.798 |
0.545 (0.125–2.371) 1.00 |
0.419 |
Notes: CEA = carcinoembryonic antigen; HR = Hazard Ratio.
*p-value < 0.05.